186 related articles for article (PubMed ID: 36429070)
1. Immune Checkpoint Inhibitor (ICI) Genes and Aging in Clear Cell Renal Cell Carcinoma (ccRCC): Clinical and Genomic Study.
Al-Danakh A; Safi M; Alradhi M; Chen Q; Baldi S; Zhu X; Yang D
Cells; 2022 Nov; 11(22):. PubMed ID: 36429070
[No Abstract] [Full Text] [Related]
2. Immune checkpoint inhibitor (ICI) genes and aging in malignant melanoma patients: a clinicogenomic TCGA study.
Safi M; Jin C; Aldanakh A; Feng P; Qin H; Alradhi M; Zhang L; Zhang J; Adlat S; Zhao Y; Liu J
BMC Cancer; 2022 Sep; 22(1):978. PubMed ID: 36100891
[TBL] [Abstract][Full Text] [Related]
3. A New Signature That Predicts Progression-Free Survival of Clear Cell Renal Cell Carcinoma with Anti-PD-1 Therapy.
Lin J; Cai Y; Ma Y; Pan J; Wang Z; Zhang J; Liu Y; Zhao Z
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982415
[TBL] [Abstract][Full Text] [Related]
4. Eosinophilic features in clear cell renal cell carcinoma correlate with outcomes of immune checkpoint and angiogenesis blockade.
Yoshida T; Ohe C; Ikeda J; Atsumi N; Ohsugi H; Sugi M; Higasa K; Saito R; Tsuta K; Matsuda T; Kinoshita H
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34580162
[TBL] [Abstract][Full Text] [Related]
5. DDX39 as a predictor of clinical prognosis and immune checkpoint therapy efficacy in patients with clear cell renal cell carcinoma.
Bao Y; Jiang A; Dong K; Gan X; Gong W; Wu Z; Liu B; Bao Y; Wang J; Wang L
Int J Biol Sci; 2021; 17(12):3158-3172. PubMed ID: 34421357
[TBL] [Abstract][Full Text] [Related]
6. Interleukin 20 receptor subunit beta (IL20RB) predicts poor prognosis and regulates immune cell infiltration in clear cell renal cell carcinoma.
Zhang H; Liu Y; Wang B; Wang C
BMC Genom Data; 2022 Jul; 23(1):58. PubMed ID: 35883015
[TBL] [Abstract][Full Text] [Related]
7. Identification of a novel combination treatment strategy in clear cell renal cell carcinoma stem cells with shikonin and ipilimumab.
Lyu C; Stadlbauer B; Wang L; Buchner A; Pohla H
Front Immunol; 2023; 14():1186388. PubMed ID: 37622107
[TBL] [Abstract][Full Text] [Related]
8. Identification of Novel Prognostic Signatures for Clear Cell Renal Cell Carcinoma Based on ceRNA Network Construction and Immune Infiltration Analysis.
Zhou L; Ye J; Wen F; Yu H
Dis Markers; 2022; 2022():4033583. PubMed ID: 35320950
[TBL] [Abstract][Full Text] [Related]
9. 53 years old is a reasonable cut-off value to define young and old patients in clear cell renal cell carcinoma: a study based on TCGA and SEER database.
Tang F; Lu Z; He C; Zhang H; Wu W; He Z
BMC Cancer; 2021 May; 21(1):638. PubMed ID: 34051738
[TBL] [Abstract][Full Text] [Related]
10. Immune-Associated Gene Signatures Serve as a Promising Biomarker of Immunotherapeutic Prognosis for Renal Clear Cell Carcinoma.
Wang Q; Tang H; Luo X; Chen J; Zhang X; Li X; Li Y; Chen Y; Xu Y; Han S
Front Immunol; 2022; 13():890150. PubMed ID: 35686121
[TBL] [Abstract][Full Text] [Related]
11. A radiogenomics biomarker based on immunological heterogeneity for non-invasive prognosis of renal clear cell carcinoma.
Gao J; Ye F; Han F; Jiang H; Zhang J
Front Immunol; 2022; 13():956679. PubMed ID: 36177018
[TBL] [Abstract][Full Text] [Related]
12. Low expression of ferritinophagy-related NCOA4 gene in relation to unfavorable outcome and defective immune cells infiltration in clear cell renal carcinoma.
Mou Y; Wu J; Zhang Y; Abdihamid O; Duan C; Li B
BMC Cancer; 2021 Jan; 21(1):18. PubMed ID: 33402128
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy.
Graham J; Wells JC; Dudani S; Gan CL; Donskov F; Lee JL; Kollmannsberger CK; Meza L; Beuselinck B; Hansen A; North SA; Bjarnason GA; Sayegh N; Kanesvaran R; Wood LA; Hotte SJ; McKay RR; Choueiri TK; Heng DYC
Eur J Cancer; 2022 Aug; 171():124-132. PubMed ID: 35717820
[TBL] [Abstract][Full Text] [Related]
14. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Rabjerg M
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
[TBL] [Abstract][Full Text] [Related]
15. The cuproptosis-associated 13 gene signature as a robust predictor for outcome and response to immune- and targeted-therapies in clear cell renal cell carcinoma.
Yuan H; Qin X; Wang J; Yang Q; Fan Y; Xu D
Front Immunol; 2022; 13():971142. PubMed ID: 36131921
[TBL] [Abstract][Full Text] [Related]
16. Development of a novel gene signature to predict prognosis and response to PD-1 blockade in clear cell renal cell carcinoma.
Yin X; Wang Z; Wang J; Xu Y; Kong W; Zhang J
Oncoimmunology; 2021; 10(1):1933332. PubMed ID: 34262797
[TBL] [Abstract][Full Text] [Related]
17. Integrated analysis of immune-related gene subtype and immune index for immunotherapy in clear cell renal cell carcinoma.
Bai D; Chen S; Feng H; Yin A; Lu J; Ma Y; Sugiyama H
Pathol Res Pract; 2021 Sep; 225():153557. PubMed ID: 34329838
[TBL] [Abstract][Full Text] [Related]
18. Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors.
Brown JT; Liu Y; Shabto JM; Martini D; Ravindranathan D; Hitron EE; Russler GA; Caulfield S; Yantorni L; Joshi SS; Kissick H; Ogan K; Nazha B; Carthon BC; Kucuk O; Harris WB; Master VA; Bilen MA
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326170
[TBL] [Abstract][Full Text] [Related]
19. Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors.
Zhang L; Han X; Shi Y
JAMA Netw Open; 2020 Aug; 3(8):e2013201. PubMed ID: 32845327
[TBL] [Abstract][Full Text] [Related]
20. The Immune-Related Gene HCST as a Novel Biomarker for the Diagnosis and Prognosis of Clear Cell Renal Cell Carcinoma.
Zhou Y; Wang X; Zhang W; Liu H; Liu D; Chen P; Xu D; Liu J; Li Y; Zeng G; Li M; Wu Z; Zhang Y; Wang X; DiSanto ME; Zhang X
Front Oncol; 2021; 11():630706. PubMed ID: 33968730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]